RNA interference-mediated gene silencing has the potential to block gene expression. A synthetic double-stranded small interfering RNA (siRNA) based on a sequence motif of 21 nucleotides from human papillomavirus 16 (HPV16) E6E7 bicistronic RNA was found to be a potent siRNA that suppresses expression of both the E6 and E7 oncogenes in HPV16
Introduction
RNA interference (RNAi) mediated through doublestranded (ds), small interfering RNA (siRNA) has been widely accepted as a gene-silencing tool in invertebrate and vertebrate cells and has potential clinical applications for therapeutic gene silencing (Dykxhoorn et al., 2003) . One means of generating an siRNA is through the processing of a dsRNA by a ribonuclease-III-like enzyme, Dicer (Zamore et al., 2000; Elbashir et al., 2001; Provost et al., 2002; Zhang et al., 2002) . In the resulting siRNA, the antisense (As) strand siRNA base pairs with the targeted region of the mRNA in a sequencespecific manner, leading to the degradation of the mRNAs (Martinez et al., 2002; Schwarz et al., 2003) or the inhibition of the mRNA translation (Doench et al., 2003; Zeng et al., 2003) . Similarly, a synthetic 21-nucleotide (nt) dsRNA containing 19 base pairs with 2-nt, 3 0 overhanging ends can be introduced experimentally into cells, triggering siRNA-mediated gene silencing (Hammond et al., 2000; Elbashir et al., 2001; Yu et al., 2002) .
Cervical infection with high-risk human papillomaviruses (HPVs), such as HPV16 and HPV18, is strongly associated with development of cervical cancer. Integration of the viral genomes into the cancer cell genome is characteristic of infection with these HPVs. Thus, the majority of cervical cancer cell lines established from cervical cancer permanently carry these virus genomes and express two viral oncoproteins, E6 and E7, which inactivate, respectively, p53 and pRb (Scheffner et al., 1990; Boyer et al., 1996; Gonzalez et al., 2001) .
HPV16 E6 (16E6) and E7 (16E7) are expressed as a single bicistronic transcript (16E6E7) from the same promoter, p97 (Smotkin and Wettstein, 1986) . The bicistronic transcript has three exons and two introns, which undergo alternative RNA splicing to produce both the E6 and E7 proteins (Zheng et al., 2004) . Several approaches have been taken to block 16E6 and 16E7 expression experimentally in cervical cancer cell lines and some promising results have been obtained. These include viral E2-mediated suppression of the p97 promoter (Goodwin et al., 2000) and siRNA-mediated silencing of E6 or E7 expression (Jiang and Milner, 2002; Butz et al., 2003; Yoshinouchi et al., 2003) . For this study, we chose an siRNA targeting a region downstream of all three alternative 3 0 splice sites in the E7 coding region (Zheng et al., 2004) . Theoretically, this siRNA should be potentially more 16E6E7-suppressive. In addition, we also attempted to obtain persistent suppression of HPV16 E6E7 expression by stably expressing the 16E7-specific siRNA in cervical cancer cell lines. To our surprise, we found that, although the stably transfected siRNA continued to be expressed in long-term culture, it retained its inhibitory function only for a short period.
Results
Transient transfection of synthetic HPV16 E7 siRNA silences expression of both the E6 and E7 oncogenes The synthetic E7 dsRNA 198 used in this report has met six of eight criteria of siRNA design (Reynolds et al., 2004) and targets a region downstream of all three alternative 3 0 splice sites in the 16E6E7 bicistronic RNA (Figure 1a ). Unlike other HPV16 E6 or E7 siRNAs described (Jiang and Milner, 2002; Butz et al., 2003; Yoshinouchi et al., 2003) , this siRNA duplex aims to degrade all unspliced and spliced isoforms of the E6E7 RNA and to suppress expression of both the E6 and E7 oncogenes, which are essential for HPV16 oncogenesis in the cervix (Howley and Lowy, 2001; zur Hausen, 2002) .
GFP expression was efficiently suppressed in a dosedependent manner when 293 cells were cotransfected with the synthetic E7 siRNA 198 and a plasmid expressing GFP-E6 or GFP-E7 (Figure 1b) . Transfection of HPV16
þ CaSki and SiHa cells derived from cervical cancer with the synthetic E7 siRNA also showed efficient inhibition of E6E7 gene expression: cell growth was inhibited (Figure 1c ), E6E7 RNA ( Figure 1d ) and E7 protein expression (Figure 1e ) decreased, and cellular Total cell RNA was prepared after 24 h of transfection with 20 nM E7 siRNA or NS siRNA. Cellular cyclophilin RNA was used for normalization of sampling as described (Tang and Zheng, 2002) . (e) Inhibition of HPV16 E7 expression and accumulation of p53 and p21 proteins in CaSki cells 48 h after transfection with HPV16 E7 siRNA or NS siRNA. HPV16 E7 protein is an E7 protein expressed from bacteria used as a control for the Western blot.
siRNA-mediated HPV16 oncogene silencing S Tang et al protein p53 and p21 expression (Figure 1e ) increased. More than 94% of CaSki and SiHa cells could be efficiently transfected with siRNA 198 in our experimental conditions and the resulting decreases of both the E6 and E7 oncogene expression in these cervical cancer cells promoted cell cycle arrest at G1 for most transfected cells (77% for CaSki and 86% for SiHa) and consequently cell growth arrest. The majority of the transfected cells was viable (over 95%) by trypan blue exclusion assay and over 90% of the cells did not undergo apoptosis in our fluorescence-activated cell sorting (FACS) analysis with annexin V staining. This observation is consistent with other reports demonstrating that silencing of HPV16 or 18 E6 and E7 oncogene expression by RNAi confers no signs of significant apoptosis (Jiang and Milner, 2002; Hall and Alexander, 2003) .
A set of multiprobes was also utilized to assess various effects of silencing HPV16 E6 and E7 oncogene expression in both CaSki and SiHa cells on expression of cell-cycle-related genes by RNase protection assay (RPA) and showed that, among all 11 genes examined, p21 was the only gene that had been upregulated (Figure 2 ). Data suggest that the E7 siRNA-mediated E6 reduction in HPV16 þ cervical cancer cells led to stabilize p53 and consequently an increased p53 transactivation of p21 transcription.
Stable expression of an HPV16 E7 siRNA in cervical cancer cell lines silences both E6 and E7 expression at early cell passages When inserted downstream of the pol III promoter in a mammalian expression vector, pSUPER (Brummelkamp et al., 2002) , the siRNA 198 was expressed as a short hairpin RNA (shRNA) structure ( Figure 3a ) and was processed into siRNAs ( Figure 3b ) in the cells with stable E7 siRNA transfection derived from the HPV16 þ cervical cancer cell lines, CaSki and SiHa. The As strand of the siRNA with the correct size (21 nts) was detected at variable levels by Northern blot (Figure 3b ) using a 32 P-labeled sense (S) oligo, whereas the S strand was barely detectable with a 32 P-labeled As oligo, suggesting efficient unwinding of the duplex RNA and degradation of the released S strand (Schwarz et al., 2003) . Consistent with this, E7 expression was suppressed to various degrees among the stably transfected cells, with CaSki C-2 cells conferring the best E7 silencing (Figure 3c ). CaSki C-3 and SiHa S-3 cells had little E7 siRNA expression ( Figure 3b ) and did not show decreased HPV16 E7 expression (Figure 3c ). However, it is notable that both CaSki C-1 and SiHa S-2 cells expressed abundant E7 siRNA (Figure 3b ), but provided only limited inhibition of the E7 expression (Figure 3c ), indicating that siRNA function was restrained in these cells.
Suppression of siRNA function in cells with stable expression of E7 siRNA Owing to existence of restrained siRNA function in both CaSki C-1 and SiHa S-2 cells even at the initial selection, CaSki-derived C-2 cells were chosen for further study of how silencing both E6 and E7 expression affects expression of other cellular genes. However, loss of the siRNA-mediated E7 silencing became evident over time, as E7 expression reappeared in the C-2 cells (Figure 4a ) despite the continued expression of the E7 siRNA at the same level as at earlier times (Figure 4b ). Seven single-cell subclones were subsequently isolated from the C-2 cells. Among the single-cell subclones, three (B12SC, D4SC and H7SC) retained strong siRNA activity for silencing E6E7 expression with altered expression of p53 and p21 proteins, whereas four other subclones, A3SC, B3SC, C2SC and H8SC, had no or only weak siRNA activity, even though all of which expressed a high level of the E7 siRNA (Figure 4c and d) . Subclone D4SC was chosen to determine whether the loss of siRNA function in the C-2 cells could be replicated with increasing numbers of D4SC cell passages. The data shown in Figure 4e confirmed that the efficiency of the þ cervical cancer cell lines, CaSki or SiHa and total cell RNA was prepared from each cell line after 24 h of transfection. Approximate 30 mg of total cell RNA were hybridized to hCC-2 multiprobes (B4 Â 10 6 cpm) and then subjected to RNase A/T1 digestion. RNA fragments protected were resolved in a 8% denaturing PAGE gel. Multiprobes undigested were run in parallel as controls and their corresponding protected products from total cell RNA were indicated by lines. (Yaginuma and Westphal, 1991; Kessis et al., 1993) for stably expressing shRNA-derived p53 siRNA and examined the correlation of the p53 protein levels with the expression of the p53 siRNA in the cells. Surprisingly, a loss of p53 siRNA function also became evident with increased cell passages (Figure 5a and b). When the same strategy was used to stably express lamin A/C siRNA in CaSki cells, we were unable to observe any development of suppression to lamin A/C siRNA in cells with stable expression of lamin A/C siRNA till the 57th cell passage (9 months) ( Figure 5c ).
Desensitization of mammalian cells by chronic siRNA treatment
One possible shortcoming of these experiments is that suppression of siRNA function observed in stable E7 siRNA and p53 siRNA cells developed under strong selection pressure that would not exist in a physiological environment. To address this issue, we chronically treated two different cell types, CaSki and 293 cells, with a low dose of siRNA by transient transfection every 3 days for 45 days. This approximates a constant siRNA level in the cells because transient siRNA functions most efficiently within 72 h after transfection of mammalian cells (our unpublished data). Subsequently, CaSki cells with or without chronic siRNA treatment were examined for expression levels of endogenous E7 and p53 as an indication of developing desensitization to siRNA function. The 293 cells with or without chronic siRNA treatment were cotransfected with a GFP-E6E7 expression vector along with a gene-specific siRNA and examined for efficiency of the siRNA in silencing the GFP-fusion protein. Our experiments further demonstrated that desensitization to a siRNA was inducible by chronic siRNA treatment in both types of cells. The CaSki cells receiving chronic E7 siRNA treatment responded poorly to cognate siRNA, with little change in E7 and p53 protein expression (compare lanes 3, 4 in Figure 6a and their correspondent bars in Figure 6b ). In contrast, the cells that had not previously received E7 siRNA treatment responded efficiently to transient transfection of this siRNA, with decreased E7 and increased p53 expression (compare lanes 1, 2 and 5, 6 in Figure 6a and their correspondent bars in Figure 6b ).
The same was true for the 293 cells treated chronically with the siRNA. The 293 cells receiving chronic E7 siRNA treatment responded poorly to E7 siRNA, and did not effectively silence GFP-E6 expression (data not shown).
Cells suppressing an endogenous siRNA are sensitive to exogenously provided synthetic siRNAs by transient transfection To determine whether a cell suppressing one particular shRNA-derived siRNA is also sensitive to another þ cervical cancer cells, CaSki and SiHa, transfected with the plasmid pST66 or pSUPER vector control, were grown in the presence of blasticidin S in the culture medium and the blasticidin S-resistant cells were selected to grow into a confluent monolayer for further analysis. Total cell RNA extracted from those cells stably transfected with the plasmid pST66 (CaSki for C-1 to C-3 and SiHa for S-2 to S-3) or with the pSUPER vector only (CaSki for C-V and SiHa for S-V) was tested for the presence of HPV16 E7 siRNA by Northern blot (b). Protein samples extracted from the stable siRNA cells were examined for HPV16 E7 expression by Western blot (c). Sample loading was normalized with U6 snRNA for Northern blot (b) and b-tubulin for Western blot (c).
siRNA-mediated HPV16 oncogene silencing S Tang et al synthetic siRNA duplex, E7 siRNA-suppressive C-2 cells were compared with E7 siRNA-sensitive C-V cells for their sensitivity to several transiently transfected synthetic siRNAs. We first compared siRNA levels in CaSki cells by transient transfection and stable transfection. Although only 1 nM siRNA was used for transient transfection, amount of the synthetic siRNA associated with the cells was much greater than the shRNA-derived endogenous siRNA expressed in C-2 or D4SC cells (Figure 7 ). Despite this difference, C-2 cells required a little higher dose of synthetic E7 siRNA to mediate a similar level of E7 silencing conferred by a relatively low dose of synthetic E7 siRNA in C-V cells by transient transfection (Figure 8a) . Furthermore, C-2 cells were found to be sensitive to other synthetic siRNA 210 (data not shown), which targets another region of 16E6E7 (Yoshinouchi et al., 2003) , and to a low dose (5 nM) of synthetic p53 siRNA duplex (Figure 8b ), resulting in silencing of these individual genes. The same is true for D4SC cells in responding to a low dose (5 nM) of synthetic p53 siRNA (Figure 8b ). This indicates that the cells insensitive to a stably expressed siRNA are still sensitive to other synthetic siRNAs by transient transfection. (a) Reappearance of 16E7 in CaSki-derived C-2 cells stably expressing HPV16 E7 siRNA as an indication of loss of E7 siRNA function with additional cell passages. E7 expression in protein samples prepared at passage 4 and at passage 6 was compared by Western blot. (b) Loss of E7 siRNA function in the C-2 cells at later cell passages was not due to decreased expression of E7 siRNA. Total cell RNA was probed for sense (S) or antisense (As) strand siRNA expression by Northern blot with a 32 P-labeled As or S oligo or a U6-specific oligo as a normalization of sampling. (c) Expression of E7 siRNA in single-cell subclones. Total cell RNA extracted from each single-cell subclone or their parent C-2 cells (lane 9) or vector-control C-V cells (lane 8) was examined for As strand siRNA expression by Northern blot using a 32 P-labeled S oligo or a U6-specific oligo for sampling control. Total cell RNA isolated from CaSki cells (C, lanes 10, 11) transiently transfected with NS (lane 10) or E7 siRNA (lane 11) at 10 nM was included as a cell control and a siRNA size control, respectively. (d) Expression of E7, p53 and p21 in each single-cell subclone was analysed by Western blot with antibodies against HPV16 E7, p53 or p21. (e) Cell passage affects E7 siRNA function in single-cell subclone D4SC cells. Protein samples prepared from cell passage 4, 6 and 8 were examined by Western blot using antibodies against HPV16 E7 or cyclin A and compared with the protein levels in CaSki-derived vector control C-V cells. The membranes in panels a, d, and e were also blotted for b-tubulin as a sample loading control. ) . The RNA was analysed by Northern blot. Numbers in the parentheses of lanes 5-9 indicate the number of cell passages at the time used for the assays. The same membrane used for As and S siRNA strand detection was also blotted for U6 snRNA to control for sample loading.
siRNA-mediated HPV16 oncogene silencing S Tang et al Yang et al., 2005) . E7 siRNA expressed from these stable siRNA cells was processed correctly, with a size of 19 nts plus two uridines as a 3 0 overhang (Figure 9a ). Suppression to E7 siRNA expressed in these stable cells did not appear due to possible activation of an interferon response by stably expressed siRNA (Bridge et al., 2003; Sledz et al., 2003) because the expression of 2 0 5 0 -oligoadenylate synthetase mRNA in the stable 16E7 siRNA cells remained in the same level as detected in the vector control cells (data not shown).
We also wondered whether the cells lacking E7 siRNA function were capable of forming RNA-induced silencing complex (RISC). RISC is a multiprotein complex (Haley and Zamore, 2004; Pham et al., 2004) into which 21-to 23-nt siRNAs are incorporated after Dicer cleavage (Provost et al., 2002; Zhang et al., 2002) . Before the incorporation, the siRNA needs to be 5 0 phosphorylated (Nykanen et al., 2001; Martinez et al., 2002) and unwound by an adenosine triphosphate (ATP)-dependent RNA helicase (Tomari et al., 2004) . This process leads the As strand into RISC to guide RISC to its target complementary mRNA for endonucleolytic cleavage at the center of the duplexed siRNA:mRNA region, 10 nt from the siRNA 5 0 end (Elbashir et al., 2001; Schwarz et al., 2003) . As all of our stable cells expressed duplex 21-nt siRNAs, we assumed that Dicer functions well in these cells, but suppression of siRNA function in these cells might be attributable to a deficiency of RISC formation. We examined in vitro RISC formation using the synthetic E7 siRNA 198 labeled with 32 P and cytoplasmic S100 extracts prepared from C-2 (E7 siRNA-suppressive) or C-V (E7 siRNAsensitive) cells. We found that both C-2 and C-V S100 extracts conferred a likelihood of three complexes (R1, R2 and R3) (Pham et al., 2004) with the E7 siRNA (Figure 9b ), suggesting that suppression of E7 siRNA function in C-2 cells occurred at steps after RISC formation. Moreover, Northern blots, probed separately with As and S probes, demonstrated the presence of much more (>10-fold) of the siRNA As strand than the S strand in the cells with siRNA suppression (Figures 4b and 5b) , implying that unwinding of the E7 siRNA duplex and degradation of the unwound S strand had occurred normally in these cells. Thus, the observed endogenous siRNA suppression in these cells must occur at yet a later step.
Presence of a 50-kDa protein in 16E7 siRNA-resistant cells and its interaction with 16E7 siRNA We therefore proposed that there might be one or more proteins in the siRNA-resistant cells interacting with the E7 siRNA and counteracting the siRNA function after RISC formation and duplex unwinding. A UV crosslinking assay was conducted to explore whether the cytoplasmic S100 extracts contain specific E7 siRNAbinding protein(s). The E7 siRNA 198 and non-specific (NS) siRNA duplexes, end-labeled with 32 P, were examined in the presence of C-2 (16E7 siRNA-resistant) or C-V (16E7 siRNA-susceptible) cytoplasmic S100 or total cell extracts. Notably, a protein with a molecular weight of approximately 50 kDa was found specifically crosslinked to the E7 siRNA in the C-2 S100 extract, but not much so in the C-V S100 (Figure 10a , compare lanes 1, 2). This S100 crosslinking profile between E7-resistant and E7-susceptible cell lines also existed in SiHa-derived cells (data not shown). In contrast, the C-2 S100 and C-V S100 were not different in their crosslinking to the NS siRNA, which did bind a smaller protein (s) with an equal affinity for both extracts (Figure 10a , compare lanes 5, 6). The total cell extracts from either C-2 or C-V cells showed the same crosslinking profile for both Figure 9 Loss of siRNA function in cells stably expressing E7 siRNA is not due to changes of siRNA sequence and occurs after RISC formation. (a) The E7 siRNA sequence was verified by cloning of small RNA molecules from C-2 cells. An As strand E7 siRNA cloned and sequenced by this approach was shown in the chromatogram. (b) Cytoplasmic S100 extracts prepared from stable E7 siRNA-suppressive C-2 cells and -sensitive control C-V cells were compared for their capacities for RISC formation in the presence of 32 P-labeled E7 siRNA. None, E7 siRNA with no S100. Both C-V and C-2 S100 extracts conferred three RISC-like complexes (R1, R2, and R3) with E7 siRNA. The binding of the B50-kDa protein in the C-2 S100 to the 32 P-labeled E7 siRNA was ATP-dependent ( Figure 10b , compare lanes 1, 2) and could be competed out only with cold E7 siRNA (left panel of Figure 10c , compare lanes 4, 5), implying a specific interaction with the E7 siRNA. In contrast, the interaction of the smaller protein(s) with the NS siRNA in the C-2 S100 was not ATP-dependent (Figure 10b, compare lanes 3, 4) and appeared to be NS, as the interaction was inhibited by tRNA or the NS siRNA, but not by the E7 siRNA (left panel of Figure 10d , compare lanes 2-4 and 6 with lane 5). Moreover, the NS siRNA-binding protein(s) retained their RNA binding affinity in high salt (600 mM) (right panel of Figure 10d ), whereas the E7 siRNA-binding protein(s) had an optimal RNA-binding affinity only in salt conditions of less than 200 mM (right panel of Figure 10c ).
Finding of ATP requirement in E7 siRNA duplex and the B50 kDa protein interaction (Figure 10b ) implies that the siRNA-protein interaction in the C-2 S100 might exert on a unwound single strand siRNA beacuse unwinding of siRNA duplex is an ATP-dependent process (Nykanen et al., 2001) . To confirmed this presumption, both S and As single strand E7 siRNA were synthesized, labeled with 32 P at their 5 0 ends, and then compared to ds E7 siRNA duplex for protein binding and crosslinking assays. As shown in Figure  11a , the B50 kDa protein in the C-2 S100 was able to bind strongly to the As strand E7 siRNA (lane 2), but only weakly to the ds E7 siRNA duplex (lanes 3 and 4) . The similarity of the binding profiles between the As strand E7 siRNA (lane 2) and ds E7 siRNA duplex (lanes 3 and 4), along with no migration retardation of the crosslinked products in the binding of ds E7 duplex, indicates that the B50 kDa protein crosslinked siRNA was indeed the unwound, single strand As E7 siRNA. Consistently with this conclusion, the B50 kDa protein in the C-2 S100 had no binding activity for the S strand (lane 1) E7 siRNA. Instead, a protein larger than 50 kDa in the C-2 S100 was found to crosslink with S strand E7 siRNA (lane 1). All ds siRNAs used for the assays were Figure 11 The B50 kDa protein in C-2 S100 preferentially interacts with an As strand E7 siRNA. (a) Interaction of C-2 S100 proteins with single or ds siRNAs. All of 32 P-labeled, synthetic single strand E7 siRNA (sense (S) and antisense (As) strand) and their annealed (an) products (S þ As) as well as synthetic, double strand (ds) E7 siRNA 198 were compared in an equal amount for their capabilities to interact with protein(s) in C-2 S100 using UV crosslinking assays. Arrow indicates a specific siRNA binding of the B50 kDa protein. (b) Electrophoretic profiles of the 32 P-labeled, corresponding siRNAs used in (a) on a 12% native PAGE gel. Figure 10 Identification of a cellular protein that interacts with HPV16 E7 siRNA 198 in E7 siRNA-resistant cells. Total cell extracts and cytoplasmic S100 extracts were prepared from E7 siRNA-resistant C-2 cells and vector control C-V (siRNA susceptible) cells and were compared for their capacities for siRNA binding in the presence of 32 P-labeled siRNA duplexes. Arrows and arrowheads indicate, respectively, specific and nonspecific protein binding. (a) A B50 kDa protein in the cytoplasmic S100 extract of E7 siRNA-resistant C-2 cells binds specifically to the E7 siRNA. Cytoplasmic S100 and total cell extracts were compared in siRNA binding and crosslinking assays using 32 P-labeled E7 siRNA or NS siRNA (top panel). The same gel was stained by Coomassie blue for protein sampling in each binding assay (bottom panel). (b) Binding of the B50 kDa protein in C-2 S100 extract to the E7 siRNA is ATP-dependent. ATP in the C-2 S100 was depleted by treatment of the extract with 0.05 U/ml hexokinase in the presence of 20 mM glucose for 20 min at room temperature (Nykanen et al., 2001 ). The C-2 S100 with or without depletion of ATP was used for RNA-protein interactions and UV crosslinking to 32 P-labeled E7 or NS siRNA. (c) Crosslinking of the B50 kDa protein in C-2 S100 to 32 P-E7 siRNA can be competed out with cold HPV16 E7 siRNA, but not with tRNA or 100-fold excess of NS siRNA (left panel). Crosslinking was affected by the presence of high concentrations of NaCl (right panel). (d) Crosslinking of a protein smaller than 50 kDa in C-2 S100 to NS siRNA is NS and can be competed out with tRNA or 100-fold excess of NS siRNA, but not with 100-fold excess of E7 siRNA (left panel). This NS protein-siRNA interaction was not affected by the presence of high concentrations of NaCl (right panel).
siRNA-mediated HPV16 oncogene silencing S Tang et al very stable (Figure 11b ), with only a trace amount of the single strand E7 siRNAs leftover in our annealing reactions (Figure 11b, lane 3) , further confirming the existence of active unwinding activity in the reactions. Together, these data indicate that the B50 kDa protein in the C-2 S100 is E7 siRNA-specific and interacts preferentially with the As E7 siRNA unwound in an ATP-dependent manner.
Discussion
Here we have shown that a specifically targeted siRNA can effectively silence both E6 and E7 expression when transiently or stably transfected in cells derived from cervical cancer. The siRNA inhibited cell growth, decreased E6E7 RNA and E7 protein expression, and increased cellular protein p53 and p21 expression, but induced no signs of significant cell apoptosis as reported from other laboratories (Jiang and Milner, 2002; Hall and Alexander, 2003) . The E7 siRNA-mediated enhancement of p53 and p21 expression in these cervical cancer cells indicates that a reduced E6 protein expression leads to stabilization of p53 followed by p53-stimulated p21 expression (Howley and Lowy, 2001) . However, the function of this siRNA was selectively suppressed with increasing time in culture.
Suppression of siRNA function by viral suppressors has been described in plant cells (Li et al., 2002; Mallory et al., 2002; Kasschau et al., 2003) , Drosophila (Li et al., 2002) and mosquito cells (Li et al., 2004) . It has been assumed that suppression of siRNA silencing could also exist in mammalian cells, which may function as a natural defense against siRNA silencing in mammals. Our report supports this presumption and provides a direct evidence that human cells can develop a function to counteract siRNA-mediated long-term silencing of critical genes. This suppressive function appears unrelated to a viral suppressor or possible activation of an interferon response by stable expression of the siRNA (Bridge et al., 2003; Sledz et al., 2003) , nor to RNA editing (Scadden and Smith, 2001; Knight and Bass, 2002; Yang et al., 2005) . While we are preparing our manuscript for publication, other groups also reported suppression of siRNA or miRNA function by viral suppressors in mammalian cells with medically important RNA or DNA virus infections (Lu and Cullen, 2004; Lecellier et al., 2005; Soldan et al., 2005) .
Expression of both 16E6 and E7 oncogenes is critical for survival of cervical cancer cells. Silencing of HPV16 E6 and E7 expression by the shRNA-derived E7 siRNA might provide an additional selection pressure for the cells to overcome siRNA function, because all stable E7 siRNA cells were already undergoing blasticidin selection. Further experimental data support this presumption by demonstrating that a cell with stable expression of shRNA-derived p53 siRNA could become suppressive, but a cell with stable expression of lamin A/C siRNA did not. Although p53 is not an essential gene and cells without p53 have a growth advantage, p53 is a cell cycle regulator and involves many signal pathways (Vousden, 2000) . Lamin A/C is an intermediate filament protein that is not essential for cell survival and plays no role in regulation of cell function (Aebi et al., 1986) . Together, these data indicate that suppression of siRNA function in these stable cells is a selective process and depends upon the commission of a targeted gene. Perhaps, suppression to a specific siRNA in a cell may be an acquired cell immunity for cell survival. Data from desensitization of CaSki cells by chronic siRNA transfection support such a hypothesis.
Nevertheless, investigation of how cervical cancer cells could develop a resistant program in the presence of E7 siRNAs for a long term has led us to conclude that suppression of siRNA function in stably transfected CaSki cells at late passages occurs after siRNA duplex unwinding and RISC formation and might involve an siRNA-protein interaction. Our exhaustive approaches further showed that the cells with resistance to endogenous E7 siRNA, in contrast to the cells with no E7 siRNA expression, contain a cytoplasmic protein with a molecular weight of B50 kDa that specifically and characteristically interacts with E7 siRNAs. More of the same protein appeared as the C-2 cells develop resistance to the siRNA and more in SiHa S-2 cells (16E7 siRNA-resistant) than SiHa S-V cells (16E7 siRNA-susceptible) (data not shown). Convincingly, this protein preferentially binds to the As strand E7 siRNAs. Although the B50 kDa protein also binds to the E7 siRNA duplexes weakly in the C-2 S100 reactions, this was confirmed to be a result of unwinding activity of the C-2 S100 as reported in HeLa S100 extracts (Martinez et al., 2002) . Together with our data showing the presence of >10-fold more siRNA As strand than S strand in the cells with endogenous siRNA expression, our study suggests that the cytoplasmic B50 kDa protein plays a role in cell development of resistance to E7 siRNA. However, its identity and exact function(s) remain to be determined and are under active investigation. This protein appears not a HPV protein, nor one of cellular ADARs (adenosine deaminases acting on RNA), simply because of its size that is much larger than two viral oncoproteins (E6 and E7), but smaller than ADARs (Yang et al., 2005) . We therefore hypothesize that the B50 kDa protein is a cellular protein. The B50 kDa protein bound to the unwound As E7 siRNA may prevent the As siRNA from base-pairing with its target mRNA or prevent the binding of a unknown endonuclease to the ds siRNA:mRNA region. Consequently, interaction of the B50 kDa protein with the As strand siRNA blocks As siRNA-guided endonucleolytic cleavage of the mRNA. S strand siRNA 243, 5 0 -GCACACACGUAGACAUUC GUU-3 0 , and As strand siRNA 244, 5 0 -CGAAUGUCUAC GUGUGUGCUU-3 0 , used in Figure 11 , were synthesized separately as a single strand siRNA from Integrated DNA Technologies, Inc. (Coralville, IA, USA). Synthetic ds p53 siRNA (Brummelkamp et al., 2002) , GFP siRNA and NS siRNA with 52% GC content (Cat. No. D-001206-08-20) were also purchased from Dharmacon. The siRNA vectors pSUPER and pSUPER-p53 (Brummelkamp et al., 2002) were a generous gift from Dr Reuven Agami of the Netherlands Cancer Institute. pSUPER was modified by insertion of an eukaryotic selection marker, the blasticidin S deaminase gene, from a NotI and BamHI fragment of pCMV/Bsd (Invitrogen, Carlsbad, CA, USA). The corresponding E7 siRNA sequence was inserted into the modified pSUPER vector to express a shRNA structure from the resulting plasmid, pST66, in mammalian cells as described (Brummelkamp et al., 2002) . The same strategy was also applied to prepare plasmid pST83 to express lamin A/C siRNA (5 0 -GGUGGUGACGAU CUGGGCU-3 0 , Cat. No. D-001050-01-20, Dharmacon) from the modified pSUPER vector. The GFP-E6 and E7 fusion plasmids pZMZ 70 (HPV16 E6 having the E7 coding region as part of its 3 0 UTR) and pZMZ74 (HPV16 E7 only) were described in our previous publication (Tao et al., 2003) .
Cell transfection and Western blot
The efficiency of each siRNA described above was assayed in HPV16 þ cervical carcinoma cells or HPV À human 293 cells by transient transfection using Oligofectamine (Invitrogen). Transfection efficiencies were established by transfection of HPV 16 þ cervical cancer cell lines, CaSki and SiHa cells, with 40 nM of fluorescein isothiocyanate (FITC)-siRNA 198 at the same transfection conditions. Cell growth curves were determined by cell counting. Cell cycle analysis was performed by FACS in the presence of Vindelov's propidium iodide buffer (Vindelov, 1977) . Apoptotic cells were determined using annexin V-FITC detection kit I (Cat. No. 556547, BD PharMingen, San Diego, CA, USA) according to the manufacturer's instruction. All cervical cancer cell lines used for both cell cycle and apoptosis analysis were prepared at 48 h for SiHa and 72 h for CaSki after transfection with 40 nM of siRNA 198.
For stable transfection, each pSUPER-derived construct was linearized by XmnI before cell transfection was performed using Lipofectamine 2000 (Invitrogen). The transfected cells were selected in the presence of blasticidin S (10 mg/ml) in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Single cells from a cell population with stable siRNA transfection were further isolated by serial dilution in 96-well plates and grown in the same selection medium as described above. After the stable cells grew up and became confluent in the selection medium, the cells with stable siRNA transfection were subcultured in the same selection medium by cell passage every 4-5 days.
Protein extracts and total cell RNA were prepared at various time points after transfection, as described in each Figure. For Western blot analyses, protein samples (approximately 30 mg each) were resolved by NuPAGE Bis-Tris gel (Invitrogen) electrophoresis before being transferred onto a nitrocellulose membrane. The membranes were then blotted with different antibodies, including anti-p21 (6B6, BD PharMingen), anti-p53 (Ab-6, Oncogene, Cambridge, MA, USA), anti-HPV16 E7 (SC-6981, Santa Cruz, CA, USA), anti-cyclin A (SC-751, Santa Cruz), anti-lamin A/C (SC-7292, Santa Cruz) and anti-b tubulin (5H1, BD PharMingen).
RPA and Northern blot
Total cell RNA was prepared using TRIzol as recommended by the manufacturer (Invitrogen). An 16E6E7-specific As RNA probe was synthesized by in vitro transcription and used for RPA for detection of the E6E7 RNAs, as described (Zheng et al., 2004) . Antisense RNA multiprobes were prepared from a hCC-2 human cell cycle multiprobe template set (BD PharMingen, Cat. No. 556160) by in vitro transcription and used for RPA for detection of various cell-cycle-related RNA transcripts.
Expression and processing of the shRNAs from stable siRNA cell lines were examined by Northern blot using a 32 P-labeled S oligo (oZMZ379, 5 0 -GCACACACGTAG ACATTCG-3 0 ) or a 32 P-labeled As oligo (oZMZ380, 5 0 -CGAATGTCTACGTGTGTGC-3 0 ) for 16E7 siRNAs or a 32 P-labeled S oligo (oST211, 5 0 -GACTCCAGTG GTAATCTAC-3 0 ) or a 32 P-labeled As oligo (oST212, 5 0 -GTAGATTACCACTGGAGTC-3 0 ) for p53 siRNAs. Briefly, 30 mg of total RNA was resolved by electrophoresis in a 12% denaturing PAGE gel, transferred to a Hybond N membrane (NEN Life Science Products, Inc., Boston, MA, USA), prehybridized in hybridization buffer (Sigma, St Louis, MO, USA) for 1 h at 411C, and then hybridized overnight with the 32 P-labeled oligo at 411C. The membrane was washed twice, once in 2 Â SSC, 1% SDS at 371C, and once in 0.1 Â SSC, 0.5% SDS in 401C, for 20 min each wash. The radiographic data on the membrane were captured using a Molecular Dynamic PhosphorImager Storm 860 and analysed with Image Quant Software. For an RNA loading control, the membrane was deprobed with 0.1 Â SSC, 0.5% SDS at 901C for 10 min and then reprobed with a 32 P-labeled U6 small nuclear (sn) RNA-specific oligo (oST197, 5 0 -AAAATATGGAACGCTT CACGA-3 0 ).
Cloning and sequencing of siRNA expressed from siRNAresistant cell lines Total cell RNA (B600 mg) extracted from CaSki-derived stable siRNA cell line C-2 at passage 40 was resolved on a denaturing 15% PAGE gel and the RNAs with sizes of 18-30 nts were collected, reverse transcribed, PCR amplified and cloned into pCRII-TOPO vector using the TOPO TA cloning kit (Invitrogen) based on published protocols (Elbashir et al., 2001; Pfeffer et al., 2003) . The inserts were determined by DNA sequencing. S100 preparation and gel mobility shift assays Cytoplasmic S100 extracts of CaSki-or SiHa-derived cells were prepared based on published methods (Mayeda and Krainer, 1999) . Total cell extracts were prepared from the S100 preparation pellet enriched with cell nuclei by sonication in Buffer D five times (5 s each on ice) followed by centrifugation at 100 000 g for 1 h at 41C. Each gel mobility shift experiment was conducted with 5 Â 10 5 cpm of the 32 P-labeled siRNA duplex incubating with 20 mg of S100 extract in a 20-ml reaction volume containing 1 Â gel shift binding buffer (Promega, Madison, WI, USA), 1 mM ATP and 6 mg of tRNA for 20 min at 301C. The reaction mixture was then incubated on ice for 10 min before directly loading onto a prerun, 4% native PAGE gel (acrylamide/Bis ¼ 80:1) and run at 150 V at 41C for 2.5 h. After electrophoresis, the gel was dried and exposed to X-ray film.
Protein-RNA interaction Protein-RNA interaction was analysed by UV crosslinking assay. Briefly, 20 mg of S100 extract or total cell extract was siRNA-mediated HPV16 oncogene silencing S Tang et al mixed with 5 Â 10 5 cpm of 32 P-labeled siRNA in a 30-ml reaction volume containing 1 Â gel shift binding buffer, 1 mM ATP and 30 mg heparin in the presence or absence of tRNA or other competitors, as shown in Figures 10 and 11 , for 20 min at room temperature, followed by 10 min on ice. The reaction mixture was then irradiated with UV for 10 min in a UV Stratalinker (Stratagene) before being loaded onto a 4-12% NuPAGE Bis-Tris gel. After electrophoresis, the gel was fixed and stained with Coomassie blue and then dried on a filter paper and exposed to X-ray film.
